| ￥3500 | |
| Z05189-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized Complement C1s, His, Human at 0.5μg/ml (100μl/well) on the plate can bind AntiC1S Antibody, hFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 75.98 kDa | ||||
| Apparent Molecular Weight | Due to enzyme lysis glycosylation, the protein migrates to 55-60 kDa (light chain), 32-35 kDa (heavy chain) and 76-96 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized Complement C1s, His, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-C1S Antibody, hFc Tag with the EC50 of 9.6 ng/ml determined by ELISA. »
Complement C1s, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Complement C1s protease inhibitors have potential utility in the treatment of diseases associated with activation of the classical complement pathway such as humorally mediated graft rejection, ischemia-reperfusion injury (IRI), vascular leak syndrome, and acute respiratory distress syndrome (ARDS). |
| Synonyms | EDSPD2; C1 esterase;Complement Component C1s |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
